

Experiment Types	Review Required	NIH Guidelines Section
Transfer of drug resistance traits that would affect control of disease	IBC, RAC, NIH/OSP prior to initiation of experiments.	III-A
Recombinant or synthetic nucleic acids containing genes for synthesis of toxins with LD50 < 100 ng/kg	IBC, NIH/OSP prior to the initiation of experiments.	III-B
Transfer of recombinant or synthetic nucleic acids into human subjects	IBC, RAC, IRB prior to initiation of experiments.	III-C
Recombinant or synthetic nucleic acids from Risk Group 2, 3, 4 or restricted agents or use as host vector systems. Some experiments involving whole animals or plants. Large scale (>10 L) experiments.	IBC prior to initiation of experiments.	III-D (examples: adenoviral, lentiviral, retroviral vectors)
Formation of recombinant or synthetic nucleic acids comprised of < 2/3 eukaryotic virus genome. Some experiments with whole plants. Creation of transgenic rodents that require BSL1 containment.	IBC notice simultaneous with initiation of experiments.	III-E
Recombinant or synthetic nucleic acids not in organisms or viruses. Most work with K-12 strains of <i>E. coli</i> . Purchase or transfer of transgenic rodents that require BSL1 containment.	Exempt from NIH Guidelines. IBC approval required to assess biosafety levels and containment.	III-F